Generic Name:
pegfilgrastim
Project Status:
Complete
Therapeutic Area:
Febrile neutropenia in non-myeloid malignancies
Manufacturer:
BGP PHARMA ULC
Call for patient/clinician input open:
Brand Name:
Fulphila
Project Line:
Reimbursement Review
Project Number:
SE0588-000
Call for patient/clinician input closed:
Details
Biosimilar:
Yes
Manufacturer Requested Reimbursement Criteria1:
Be listed as the preferred pegfilgrastim product to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-neoplastic drugs.
Submission Type:
Initial
Fee Schedule:
Schedule D
Indications:
Febrile neutropenia in non-myeloid malignancies
Recommendation Type:
N/A
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.